RxDoctor Payments Data

Antonio Wong, MD

Internal Medicine · Edinburg, TXNPI 1932206315

Payments from drug & device makers

$4,963in general payments, 2019–2025

Across 309 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$658
  • GSK$603
  • AbbVie$385
  • Lilly USA, LLC$351
  • Astellas Pharma US Inc$346
  • Boehringer Ingelheim$344
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,85598%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,963 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,048
Medicare patients
196
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide374$489,434
JardianceEmpagliflozin394$468,036
FarxigaDapagliflozin Propanediol181$218,977
MounjaroTirzepatide145$204,609
LinzessLinaclotide97$117,569
JanuviaSitagliptin Phosphate88$110,811
EliquisApixaban99$102,165
TrulicityDulaglutide58$80,943
XareltoRivaroxaban64$80,266
MyrbetriqMirabegron80$79,113
Tresiba Flextouch U-100Insulin Degludec86$77,450
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog68$72,584
Tresiba Flextouch U-200Insulin Degludec81$72,496
XifaxanRifaximin13$55,016
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog60$42,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$344$497,731429 claims
Novo NordiskOzempic$658$489,434374 claims
Lilly USA, LLCMounjaro, Trulicity$351$285,552203 claims
AstraZenecaFarxiga, Brilinta$312$223,907193 claims
AbbVieLinzess$385$117,56997 claims
PfizerEliquis$160$102,16599 claims
Johnson & JohnsonXarelto$151$80,26664 claims
Astellas Pharma US IncMyrbetriq$346$79,11380 claims
GSKTrelegy Ellipta, Breo Ellipta$603$69,32383 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$339$55,01613 claims
AmgenProlia$73$22,60814 claims
NovartisEntresto$72$21,76814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →